COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
Defence Therapeutics Inc. to participate in the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024, presenting their novel Radio-Immuno-Conjugate (RIC) for cancer treatment -
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Defence Therapeutics Inc.'s AccuTOX published in the prestigious Journal of Translational Medicine along with preclinical data on AccuTOX as an anti-cancer molecule. Study highlights AccuTOX's superior therapeutic properties and versatility for different cancer treatments -
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
Defence Therapeutics strengthens and expands global patent protection on key technologies, including vaccine enhancer platform and ADC platform technology. The new patents and allowances showcase the company's commitment to innovation in biopharmaceuticals
